Peregrine Pharmaceuticals Inc. (Nasdaq: PPHM) reported that advanced lung cancer patients taking its bavituximab in a mid-stage clinical trial lived twice as long as patients receiving only chemotherapy. The stock price leaped $1.43 to close at $4.50.